Relapse remains the major cause of mortality post hematopoietic cell transplantation (HCT) for pediatric acute leukemia. Previous research suggests that reducing the intensity of calcineurin inhibitor based graft versus host disease (GVHD) prophylaxis may be an effective strategy in abrogating the risk of relapse in pediatric patients undergoing matched sibling donor (MSD) HCT. We reasoned that benefits of this strategy could be maximized by selectively applying it to those patients least likely to develop GVHD. We conducted a study of risk for GVHD, to risk stratify patients based on age. Patients <18 years with leukemia who received myeloablative, T cell-replete MSD bone marrow transplantation and calcineurin inhibitor based GVHD prophylaxis between 2000-2013 entered into the Center for International Blood and Marrow Transplant Research registry were included. Cumulative incidence of grade 2-4 acute GVHD was 19%, grade 3-4 acute GVHD 7%, and chronic GVHD 16%. Compared to age 13-18 years, age 2-12 years was associated with a lower risk for grade 2-4 acute GVHD (hazard ratio We conclude that acute GVHD rates have decreased significantly over time, and children 2-12 years are at very low risk for acute and chronic GVHD. These results should be validated in an independent analysis, as these patients with high-risk malignancies may be good candidates for trials of reduced GVHD prophylaxis.
Introduction
Relapse is the primary source of failure of allogeneic hematopoietic cell transplantation (HCT) for pediatric acute leukemia.(1-3) Results of randomized controlled trials conducted in the 1980s and 1990s in children and adults receiving myeloablative conditioning, HLA matched sibling donor (MSD) marrow transplantation and cyclosporine with short course methotrexate for graft versus host disease (GVHD) prophylaxis, indicate that the risk for relapse can be mitigated by attenuating the intensity of prophylaxis -by dropping the methotrexate or lowering the cyclosporine dose. (4) (5) (6) (7) This research, however, also suggests that the benefits of such reductions could be offset, at least in part, by increases in transplant related mortality (TRM) driven by increased acute GVHD (aGVHD). (6, 7) Further investigation of attenuated GVHD prophylaxis regimens is needed in pediatric MSD HCT, where the risk for GVHD is low. (8, 9) Studies of risk for GVHD in pediatric patients suggest that even within the pediatric age group, patients can be risk stratified using recipient and donor age. (10, 11) We, therefore, hypothesized that it would be feasible to apply statistical methods to identify an age group within pediatric MSD recipients who are at very low risk of aGVHD, one that would be ideal for trials of attenuated GVHD prophylaxis. As a first step to test this hypothesis, using data drawn from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we conducted the largest study to date of risk for GVHD in pediatric HLA MSD HCT. To maximize the relevance of our findings to HCT for pediatric acute leukemia, we limited our sample to patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and attempted to mirror the approach most commonly employed in this setting by limiting inclusion to marrow grafts and myeloablative conditioning.
Patients and Methods

Patients
This is a retrospective analysis of 476 patients entered into the CIBMTR database. The CIBMTR is a voluntary working group of more than 450 transplantation centers that contribute detailed data on consecutive hematopoietic cell transplantation to a Statistical Center at the Medical College of Wisconsin in Milwaukee, Wisconsin. Participating centers are required to report all transplants consecutively, and compliance is monitored by on-site audits. All patients provided written informed consent in accordance with the Declaration of Helsinki for data submission and research participation. This study was approved by the Institutional Review Board of the Medical College of Wisconsin.
Inclusion criteria
Patients younger than 18 years with AML or ALL in 1 st or 2 nd complete remission (CR), who received myeloablative conditioning, T cell-replete HLA MSD bone marrow grafts and calcineurin inhibitor based GVHD prophylaxis between 2000-2013 were included. Patients who received a lymphocyte depleting antibody (ATG/Campath) within the conditioning regimen were excluded. Preparative regimens and GVHD prophylaxis with small cohort sizes (<5) were excluded in an effort to study a homogeneous population.
Statistical analysis
Acute GVHD grading was based on the 1994 Consensus criteria.(12) Chronic GVHD (cGVHD) was described according to the Seattle Criteria, (13) and CIBMTR severity grading was applied. (14) The 'optimal' cut points for recipient age were determined using a likelihood ratio test, based on the univariate Cox model for grade III-IV aGVHD. These cut points were used to define the age groups included in all final models.
Patient, disease, and transplant-related factors were compared among the three age groups using χ 2 for categorical variables and Kruskal-wallis test for continuous variables. Probabilities for overall survival (OS) were calculated using the Kaplan-Meier method. Comparison of survival curves was done using the log-rank test. Estimates of aGVHD, cGVHD, TRM and relapse were calculated according to the cumulative incidence, with death as a competing risk for GVHD and relapse.
The Cox proportional hazards models were used to examine the effects of recipient age on aGVHD, cGVHD, relapse, TRM, disease-free survival, and OS, while adjusting for other clinical variables. Variables considered included recipient-related variables (age, sex, performance score, diagnosis, and disease stage at transplantation), donor-related variables (donor-recipient birth order, donor-recipient sex match, donor-recipient cytomegalovirus serology), and transplant-related variables (total body irradiation-TBI -containing vs non-TBI containing conditioning, total nucleated cell dose, GVHD prophylaxis, time from diagnosis to transplant and transplant time period). All clinical variables were tested for the affirmation of the proportional hazards assumption. A stepwise forward model selection procedure was used to select adjusted clinical variables for each outcome with a threshold of 0.05 for both entry and stay. The center was adjusted as a random effect. Interactions between the main variable and adjusted covariates were tested and none were detected at 0.01 significance level. To adjust for multiple testing, a 2-sided p-value of <0.01 was considered statistically significant. When the overall p-value of our main testing variable (i.e., patient age) was <0.01 for an endpoint, a threshold of p-value< 0.05/3=0.016 was used for significance of a particular comparison. Analysis was performed using SAS version 9.3 (SAS Institute, Cary, IN).
Results
A total of 476 patients, from 101 centers, met inclusion criteria. Median age of the recipients at time of HCT was 10.1 years. Forty seven percent had AML in 1 st CR, 8% AML in 2 nd CR, 21% ALL in 1 st CR, and 24% ALL in 2 nd CR. Using grade III-IV aGVHD as the primary outcome, we identified two cut points, 2 years and 13 years, and used them to define 3 groups for recipient age: < 2 years (n=60), 2 to 12 (n=255) years and 13-17 years (n=162). The majority (73%) of patients received cyclosporine and Methotrexate for GVHD prophylaxis, with similar frequencies across the three age groups. In the youngest age group (<2 years), 76% of patients received busulfan based conditioning, whereas roughly half of the patients in the other age groups received TBI-based conditioning. Total nucleated cell (TNC) dose was higher for the youngest age group. Among the <2 year age group, 41% received a TNC dose >5 × 10 8 /kg, whereas 14% of patients age 2-12 years and 6% of patients 13-17 years received that dose. As expected, donor and recipient age were highly correlated. Baseline patient, donor and transplant characteristics are shown in table 1.
Acute Graft Versus Host Disease
The cumulative incidence of grade II-IV aGVHD for all patients at 100 days post-transplant was 19% (95% confidence interval, CI, 16-23%). As shown in figure 1A , children between 2-12 years at the time of transplant developed significantly less grade II-IV aGVHD (13%) compared to children younger than 2 years (24%) or adolescents older than 13 years (28%, p<0.001). The majority of patients developed grade II-IV aGVHD in the first month posttransplant, and median day of onset did not differ by age (<2, day 21; 2-12, day 24; >=13, day 24). Target organ involvement did not differ by age (supplemental table 1). Out of patients with grade II-IV aGVHD, the proportion of patients with gut GVHD did not differ by age (<2, 8/14; 2-12, 18/35; >=13, 28/45). Multivariate analysis confirmed the protective effect of age 2-12 years (table 2). After adjusting for GVHD prophylaxis regimen, Karnofsky score, and year of transplant, children aged 2-12 were at significantly less risk for grade II-IV aGVHD (HR 0.42, CI 0.26-0.7, p=0.0008) compared to children 13 years or older. Interestingly, children younger than 2 years were also at less risk for grade II-IV aGVHD (HR 0.54, CI 0.26-1.08, p=0.083) after adjustment for these other risk factors, but this result was not statistically significant. The multivariate analysis confirmed the significant effect of other risk factors on the development of grade II-IV aGVHD. Children who received prophylaxis with Cyclosporine +/− other agents (71% CSA only, 17% CSA + mycophenolate, 12% CSA + steroids) had a higher risk compared to those receiving cyclosporine and methotrexate (HR 3. The cumulative incidence of grade III-IV aGVHD at 100 days for all patients was 7% (95% CI 5-10%). As shown in figure 1B , children between the ages of 2-12 years developed significantly less grade III-IV aGVHD (3%), compared to children younger than 2 years (9%) and older than 13 years (14%, p <0.001). Multivariate analysis confirmed the protective effect of age 2-12 years. After adjusting for year of transplant, children aged 2-12 years had significantly less risk for grade III-IV aGVHD (HR 0.23, CI 0.1-0.54, p =0.001) compared to children 13 years or older. Children younger than 2 years had a lower risk, but that result was not statistically significant ( table 3 ). A subset analysis limited to patients receiving CSA/MTX ± other showed a persistent influence of time period on risk of grade II-IV and III-IV aGVHD (supplement tables 4). Constructing the model with a less stringent p-value of 0.2 showed consistent results with regards to effect of recipient age (data not shown).
Chronic Graft Versus Host Disease
The cumulative incidence of cGVHD at 1 year post-transplant for all age groups was 16% (95% CI 13-20%). As shown in figure 1C , it was lowest for children 2-12 years (10%), with a similar incidence in children younger than 2 years (15%), and the highest incidence observed in children 13 years or older (27%, p <0.001). Fifty percent of patients were diagnosed within the first 6 months and almost all patients were diagnosed within the first year post transplant. Among cGVHD cases, the majority of patients <13 years had mild disease, while 51% of patients 13-17 years had moderate -severe disease (supplement table  3 ).
Multivariate analysis confirmed the protective effect of age (table 2). Children 2-12 years were at significantly lower risk for cGVHD (HR 0.32, CI 0.19-0.54, P <0.001) compared to children 13 years or older. Children <2 years were also at less risk (HR 0.36, CI 0.16-0.82, p=0.0156), but the result was not statistically significant. GVHD prophylaxis was also important; compared to CSA/MTX ± others, tacrolimus based regimens and the CSA ± others had a HR of 2.35 (CI 1.18-4.7, p=0.015) and 2.40 (CI 1.22-4.7, p=0.013), respectively (table 2).
The use of a donor younger than the recipient significantly decreased the risk of cGVHD (HR 0.43, 95% CI 0.26-0.72, p= 0.0014). Having a younger donor significantly decreased the risk in patients 13-17 years (HR 0.42, 95% CI 0.22-0.80, p=0.0086), but not 2-12 years (HR 0.39, 95% CI 0.13-1.21, p=0.1045). In the 13-17 age group, the protective effect of a younger donor was not explained by recipient age, as the median recipient age was 16 years (range 13-17) for both patients with younger and older donors. In the 2-12 age group, median recipient age was 10 (range 3-12) for patients with younger donors and 7 (3-12) for patients with older donors.
Survival
OS was 81% (95% CI 78-85%) at 1 year post transplant. TRM was 2% (95% CI 1-3%) at 100 days and 4% (95% CI 3-6%) at 1 year. In multivariate analyses (table 3) , there was no difference in OS, relapse or leukemia-free survival between the age groups. Analysis of TRM revealed a non-statistically significant decrease in risk for patients 2-12 years (HR 0.34, 95% CI 0.15-0.77, p=0.01). These analyses did not reveal an impact for other patient, donor, or transplant risk factors.
Discussion
Our analysis of GVHD risk in pediatric patients receiving MSD bone marrow transplantation (BMT) for acute leukemia, most of whom received a calcineurin inhibitor with methotrexate for prophylaxis, underscores the important influence of age. Our results indicate that children 2-12 are at very low risk for GVHD. In this age group, the cumulative incidence of grade III-IV aGVHD was only 3% and cGVHD, most of which was mild, was only 8%. Remarkably, in our dataset, there were no cases of grade III-IV in this age group out of 120 HCT performed after 2004. It is important to note that the vast majority of patients in our sample were drawn from North America. Our results, therefore, may not be applicable to European centers, where the use of cyclosporine alone for MSD transplantation for children with acute leukemia is standard.(15) Our data set was not large enough to accommodate a validation set.
Other studies have shown that recipient age is a risk factor for GVHD. (8-11) The goal of this study was to identify a group of children at minimal risk for GVHD in the setting of MSD BMT, using statistical methods. The impetus for doing so comes from research demonstrating an association between the intensity of calcineurin inhibitor immune suppression, whether gauged by the number of agents combined with the calcineurin inhibitor, the dose or the duration of the calcineurin inhibitor, and relapse. Conversely, reducing the intensity of immune suppression can decrease the risk for relapse. (3, 5, 6, 16, 17) We reasoned that strategies to promote a graft versus leukemia (GVL) effect through lessening immunosuppression intensity in children would be optimized by applying them to patients who have the lowest risk of GVHD.
One such strategy that deserves further assessment is using cyclosporine alone. Recently published, non-comparative experience in children suggests that the European strategy of using cyclosporine alone may effectively augment the GVL effect without substantively raising the risk for GVHD and TRM. (18) This observation, however, should be confirmed in a prospective, comparative study, so that the potential of this strategy for increasing the incidence of GVHD and TRM as well as its potential to reduce relapse can be rigorously evaluated. Importantly, the possible risk of increasing TRM should be closely scrutinized. In our analysis, children 13-17 years of age had similar aGVHD incidence to that reported in adults undergoing MSD BMT for leukemia. (19) In a randomized trial of low versus standard dose cyclosporine as a single agent for GVHD prophylaxis, in children and adults, lower cyclosporine dose was associated with increased transplant related complications in patients older than 30 years, but was well tolerated in younger patients, without increase in TRM. (4) This further emphasizes the need to define a candidate age group for a large, multicenter randomized controlled trial, where reduction in GVHD prophylaxis through a calcineurin inhibitor only approach, could safely be applied to capitalize on the reduction in relapse observed in the European studies, while preserving a low TRM rate in MSD BMT.
While it is unclear why the risk for relapse in the 2 to 12 year group was not increased given the very low risk for GVHD, it is important to keep two things in mind. First, the GVL effect of allogeneic transplantation is only partly mediated by GVHD. This is especially true in AML (the majority of our sample), where the contribution of GVHD to the GVL effect is modest.(20) Secondly, our sample was not well suited for comparing relapse across age groups as it was heterogeneous with respect to disease and remission status. Moreover, we did not consider important determinants of relapse, like minimal residual disease, or other prognostic factors delineating age related differences in leukemia biology.
As in a similar CIBMTR study of aGVHD risk in adults, we only assessed the influence of recipient age.(21) Although increased donor age has been shown to be a risk factor for GVHD in two previous pediatric studies, both including patients with non-malignant as well as malignant diseases and one including unrelated as well as related donors (10, 11) , in our sample, donor and recipient age were too closely associated to discriminate their effects. We were, however, able to validate previously reported single center and CIBMTR results on the effect of birth order in MSD HCT, where a donor younger than the recipient favorably impacted risk of acute and chronic GVHD. (22, 23) In our analysis, adolescents receiving grafts from younger siblings were at decreased risk for cGVHD.
The incidence of GVHD in patients <2 years was unexpectedly higher than in those between 2 and 12 years. This finding needs to be interpreted cautiously, as it was driven by statistical methods, and thus may be related to the low sample size of only 59 patients <2 years in our cohort. However, it is conceivable that graft T cell doses, data we lacked, are higher in this group, which received the highest total nucleated cell dose doses at transplant. (24, 25) Further, larger studies will be needed to determine if young age is an independent risk factor for developing GVHD.
There was an impressive decrease in the rates of aGVHD observed over time. This is consistent with results of a CIBMTR study of unrelated donor HCT in children with leukemia. (26) In that study, including transplants performed between 1990 and 2003, risk of aGVHD was reduced after 1999. In our study, more recent time periods included a higher proportion of patients with AML, receiving non-TBI conditioning, and an increasing use of tacrolimus-based prophylaxis. The increased use of tacrolimus over time did not explain this finding, as we observed a similar effect for time period in a subgroup analysis of patients receiving cyclosporine prophylaxis. Time period was not a surrogate for above mentioned changes in practice, as excluding time period from the analysis did not bring forth any other significant factors. It is possible that other unaccounted for practice changes, such as more vigilant monitoring of trough levels, could explain the drop in risk.
In summary, this study identified a subgroup of children receiving MSD HCT for leukemia who are at low risk for GVHD, but these results should be validated before they can be employed in a clinical trial. Subsequent studies could build on these results by investigating the use of attenuated GVHD prophylaxis in this group and assessing impact on relapse through potentially promoting a GVL effect. Such an approach should be applied within the confines of a clinical trial, and could be combined with predictive biomarker parameters (27) to identify patients at higher risk of developing aGVHD and TRM. Abbreviations: CR = Complete Remission, TNC = Total Nucleated Cell, CY = Cyclophosphamide, TBI = Total Body Irradiation, BU = Busulfan, FLU = Fludarabine, CSA = Cyclosporine, MTX = Methotrexate, Tac = Tacrolimus.
* : Donor-Recipient age difference is measured as donor age -recipient age (a value of "1.0" indicates the donor is one year older than the recipient, whereas a value of "−1.0" indicates the recipient is 1 year older than the donor).
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